With high-cost specialty drugs making up an ever-greater percentage of new launches, and prices for existing brand biologics on an ongoing upward trajectory, biosimilars – lower cost alternatives to these expensive medications – brought with them the promise of lower costs for everyone. Yet, despite their potential, uptake has been slow and this promise has failed to materialize. Here’s a look at the top five challenges facing the biosimilars market today.
1. Complex Formulary Structures
Formulary management has become a significant obstacle to biosimilar adoption. When new biosimilars such as Amjevita™ were launched, their uptake was slow, not due to demand, but because of how they were positioned within formularies. The structure of these formularies often favors brand drugs driven by existing rebate structure and multi-year benefit plans making it difficult for biosimilars to compete effectively.
As a result, the market is characterized by fragmentation and slow adoption instead of a straightforward transition to more affordable treatments. Each biosimilar's array of choices and details has created new hurdles for healthcare providers and patients trying to navigate the options. This has contributed to sluggish uptake, preventing the competition from driving down prices and enhancing patient access.
2. Pricing and High Wholesale Acquisition Costs (WAC)
Biosimilars enter the market with high introductory WACs This high pricing strategy has significantly dampened uptake and, as a result, biosimilars’ impact on overall medication costs. One reason for this is the significant costs of developing and bringing biosimilars to market. The biosimilar market has also yet to reach a level of competition that effectively drives prices down. High WAC prices for biosimilars create a paradox: while the drugs are marketed as cost-saving alternatives, their affordability is often compromised.
3. Market Dynamics and Manufacturer Strategies
Strategic maneuvers by brand drug manufacturers further complicate the market dynamics surrounding biosimilars. Pay-for-delay tactics that prevent or significantly extend the period before which a lower-cost alternative is launched have led to ongoing market dominance by brand biologics and curtailed the growth of biosimilars.
4. Prescriber and Patient Hesitance
A lack of clear communication and education about biosimilars has led to hesitancy among prescribers and patients. Many remain unfamiliar with biosimilars or perceive them as unproven alternatives. This hesitance is exacerbated by the complex landscape of product characteristics, such as variations in concentration and formulations, which create additional barriers to adoption. For biosimilars to succeed, there needs to be a concerted effort to educate healthcare providers and patients on their safety, efficacy, and benefits compared to their brand-name counterparts.
5. Missed Opportunities for Cost Savings
The slow adoption of biosimilars represents a substantial missed opportunity for cost savings. Reports suggest that broader access to Humira biosimilars alone could save the healthcare system up to $6 billion annually. The current inefficiencies within the market prevent these savings from being realized, highlighting the critical need for reform in formulary and pricing strategies. To achieve the full potential of biosimilars, stakeholders must address these systemic issues and work towards creating a more favorable environment for their adoption.
In conclusion, while the promise of biosimilars remains significant, overcoming these obstacles requires coordinated efforts from all stakeholders involved in drug pricing, formulary management, and market dynamics. These challenges underscore the need for policy and practice change to unlock biosimilars' true potential in the healthcare industry.
Stay up-to-date on the latest pharmacy trends in the Pharmland podcast.